Page last updated: 2024-12-10

geranylgeranic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

geranylgeranic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(2E,6E,10E)-geranylgeranic acid : A diterpenoid obtained by formal oxidation of the CH2OH group of (E,E,E)-geranylgeraniol to the corresponding carboxylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5275521
CHEMBL ID171326
CHEBI ID84971
SCHEMBL ID430557
SCHEMBL ID16221387
MeSH IDM0119712

Synonyms (24)

Synonym
2,6,10,14-hexadecatetraenoic acid, 3,7,11,15-tetramethyl-, (2e,6e,10e)-
(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoic acid
NCGC00163653-01
geranylgeranic acid
chebi:84971 ,
CHEMBL171326
geranylgeranoic acid
(2e,6e,10e)-geranylgeranic acid
2,6,10,14-hexadecatetraenoic acid, 3,7,11,15-tetramethyl-, (z,e,e)-
2,6,10,14-hexadecatetraenoic acid, 3,7,11,15-tetramethyl-
83807-40-3
2,6,10,14-hexadecatetraenoicacid, 3,7,11,15-tetramethyl-
CCG-208213
SCHEMBL430557
35750-48-2
SCHEMBL16221387
sr-05000002342
SR-05000002342-2
SZNLKILVMCHHSD-OZFNKYQOSA-N
Q27158232
geranylgeranic?acid
3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoic acid
STARBLD0008406
AKOS040755401

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
methyl-branched fatty acidAny branched-chain fatty acid containing methyl branches only.
trienoic fatty acidAny polyunsaturated fatty acid that contains three double bonds.
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency22.33420.140911.194039.8107AID2451
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID47224In vitro inhibition of yeast cell growth of candida albicans; No inhibition2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
AID47226In vitro inhibition of yeast-to-hypha transition in candida albicans; No inhibition2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.56)18.7374
1990's2 (5.13)18.2507
2000's13 (33.33)29.6817
2010's20 (51.28)24.3611
2020's3 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]